Details
September 10, 2020
12:00PM - 1:00PM
MSHO Corporate Sponsor Zoom Meetings
Adaptive Biotech, Agios, Exelixis, Sanofi, TEVA
Zoom Meeting
Do you miss having your favorite pharma reps visit your office? MSHO will be hosting a series of Zoom lunch meetings with some of our corporate sponsors. Join your colleagues and pharma friends for 25 minutes of education and seeing each others' smiling faces!
Registration has closed. Please contact Kasie Blazevski at kblazevski@msho.org to see if space is available.
12:00 pm - 12:25 pm Meetings:
- Exelixis
- Overview: Update in front line aRCC
- Sanofi Genzyme
- Overview: Updates on Sarclisa, Libtayo, and Jevtana
- TEVA
- Overview: Discuss the benefits of Bendeka (Bendamustine) differences and the newly launched biosimilars for Rituximab and Herceptin.
12:35 pm - 1:00 pm Meetings:
- Adaptive Biotech
- Overview: clonoSEQ MRD testing in lymphoid malignancies. I will be discussing the use of testing for Minimum/Measureable Residual Disease in CLL, ALL and MM.
- Agios
- Overview: Overview of Tibsovo
For questions regarding this event, please contact MSHO at 248-385-5464 or email kblazevski@msho.org.
Add to Calendar
aCLuDhaqizCaPxAftmqF167204
09/10/2020 12:00 PM
09/10/2020 01:00 PM
false
MSHO Corporate Sponsor Zoom Meetings
Do you miss having your favorite pharma reps visit your office? MSHO will be hosting a series of Zoom lunch meetings with some of our corporate sponsors. Join your colleagues and pharma friends for 25 minutes of education and seeing each others' smiling faces!
Registration has closed. Please contact Kasie Blazevski at kblazevski@msho.org to see if space is available.
12:00 pm - 12:25 pm Meetings:
Exelixis
Overview: Update in front line aRCC
Sanofi Genzyme
Overview: Updates on Sarclisa, Libtayo, and Jevtana
TEVA
Overview: Discuss the benefits of Bendeka (Bendamustine) differences and the newly launched biosimilars for Rituximab and Herceptin.
12:35 pm - 1:00 pm Meetings:
Adaptive Biotech
Overview: clonoSEQ MRD testing in lymphoid malignancies. I will be discussing the use of testing for Minimum/Measureable Residual Disease in CLL, ALL and MM.
Agios
Overview: Overview of Tibsovo
For questions regarding this event, please contact MSHO at 248-385-5464 or email kblazevski@msho.org.
Zoom Meeting
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
